Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain
Autor:
Aguilera, Antonio
; Trastoy, Rocío
; Rodríguez-Calviño, Javier
; Manso, Tamara
; Mendoza, Carmen de
; Soriano, Vicente
Fecha:
09/2018Palabra clave:
Revista / editorial:
European Journal of Gastroenterology & HepatologyTipo de Ítem:
Articulo Revista IndexadaResumen:
Background Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual HDV and hepatitis B virus exposure. Herein, we examined the global and incident rates of HDV infections in Spain.
Patients and methods The presence of anti-HDV antibody and new HDV superinfections was examined in all HBsAg+ patients who attended one large tertiary outclinic in Spain since year 2000. Anti-HDV antibodies were tested repeatedly every 5 years in those previously negative.
Results During a median follow-up of 12 years, 478 individuals were diagnosed as HBsAg+. Overall, 64.4% were male, median age was 55 years, 88.1% were native Spaniards, 6.5% were coinfected with HIV, and 7.3% were reactive for hepatitis C virus (HCV) antibodies. A total of 19 (4%) patients had anti-HDV antibody at first diagnosis. There were no further HDV seroconversions. Most anti-HDV + patients were male (n = 12), former injection drug users (n= 13), and native Spaniards (n= 16). Coinfection with HIV was found in six, and 12 had HCV antibodies. Interestingly, three of seven women with delta hepatitis were foreigners (Asian or African), denied injection drug use, were younger than 40 years old, and negative for both HCV and HIV.
Conclusion The prevalence of chronic hepatitis delta is currently very low (< 5%) among chronic HBsAg+ carriers in Spain, with lower rates in recent years. Moreover, new incident HDV infections were not seen in 478 chronic hepatitis B carriers since year 2000, following drastic declines in injection drug use.
Este ítem aparece en la(s) siguiente(s) colección(es)
Estadísticas de uso
Año |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Vistas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
105 |
71 |
52 |
50 |
52 |
92 |
19 |
Descargas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America
Trastoy, Rocío; González-Alba, José María; Soriano, Vicente ; Rodríguez-Calviño, José Javier; de Mendoza, Carmen; Costa, José Javier; Cea, María; Barbeito, Gema; Corral, Octavio Jorge ; Gómez-Gallego, Felix ; Pérez del Molino, María Luisa; Carlos Galán, Juan; Aguilera, Antonio (Journal of Clinical Virology, 2022)Background: Hepatitis B virus (HBV) comprises 9 genotypes and multiple subgenotypes that depict differences in geographic distribution, clinical outcome and response to antiviral therapy. However, the molecular epidemiology ... -
Susceptibility to hepatitis B virus infection in adults living in Spain
Soriano, Vicente; Aguilera, Antonio; Benito, Rafael; Gonzalez-Diez, Rocio; Miro, Elisenda; Liendo, Paloma; Rodriguez-Diaz, Juan Carlos; Cabezas, Teresa; Richart, Alberto; Ramos, José Manuel; Barea, Luisa; Alvarez, Carmen; Treviño, Ana; Gómez-Gallego, Felix; Corral, Octavio Jorge; de Mendoza, Carmen (Liver International, 2023)BackgroundA protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all ... -
Hepatitis delta in patients with resolved hepatitis B virus infection
Aguilera, Antonio; Rodríguez-Calviño, Javier; Mendoza, Carmen de; Soriano, Vicente (European Journal of Gastroenterology & Hepatology, 09/2018)Background The hepatitis delta virus (HDV) causes the most aggressive form of chronic viral hepatitis. As HDV replication requires hepatitis B virus (HBV), HDV screening is limited to HBsAg+ carriers. To date, individuals ...